Talzenna
BRCA 2 Gene Mutation
Brown UniversityPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
30 Active assets in the BRCA 2 Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib M.D. Anderson Cancer Center | Phase 3 | BB |
Veliparib The University of Texas Health Science Center at San Antonio | Phase 2 | BB |
Olaparib GBG Forschungs GmbH | Phase 3 | BB |
Ovitrelle University Hospital, Ghent | Phase 4 | BB |
Carboplatin University of Washington | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Talzenna is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →